Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Sinovac PCV24 in Adults Aged ≥18 Years
NCT07543198Phase 2Completed
- Sponsor
- Sinovac Life Sciences
- Start
- Jun 2025
- Primary completion
- Feb 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Sinovac PCV24 in pneumococcal infection (7 arms), sponsored by Sinovac Life Sciences. Primary endpoints: Incidence of adverse reactions at 30 days, Pneumococcal serotype-specific opsonophagocytic assay geometric mean titer at 30 days and 3 more. Started Jun 2025; status: completed.
02
Drugs
Sinovac PCV24
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT07543198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07543198.